250 related articles for article (PubMed ID: 15995322)
1. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.
Gotlib J
Acta Haematol; 2005; 114(1):7-25. PubMed ID: 15995322
[TBL] [Abstract][Full Text] [Related]
2. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.
Gotlib J; Cross NC; Gilliland DG
Best Pract Res Clin Haematol; 2006; 19(3):535-69. PubMed ID: 16781488
[TBL] [Abstract][Full Text] [Related]
3. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
[TBL] [Abstract][Full Text] [Related]
4. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
[TBL] [Abstract][Full Text] [Related]
5. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.
Cools J; Stover EH; Wlodarska I; Marynen P; Gilliland DG
Curr Opin Hematol; 2004 Jan; 11(1):51-7. PubMed ID: 14676627
[TBL] [Abstract][Full Text] [Related]
6. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis.
Bain BJ
Am J Hematol; 2004 Sep; 77(1):82-5. PubMed ID: 15307112
[TBL] [Abstract][Full Text] [Related]
7. Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy.
Macdonald D; Cross NC
Pathobiology; 2007; 74(2):81-8. PubMed ID: 17587879
[TBL] [Abstract][Full Text] [Related]
8. Modern diagnosis and treatment of primary eosinophilia.
Tefferi A
Acta Haematol; 2005; 114(1):52-60. PubMed ID: 15995325
[TBL] [Abstract][Full Text] [Related]
9. FIP1L1/PDGFR alpha-associated systemic mastocytosis.
Yamada Y; Cancelas JA
Int Arch Allergy Immunol; 2010; 152 Suppl 1(Suppl 1):101-5. PubMed ID: 20523072
[TBL] [Abstract][Full Text] [Related]
10. Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.
Miyazawa K; Kakazu N; Ohyashiki K
Int J Hematol; 2007 Jan; 85(1):5-10. PubMed ID: 17261495
[TBL] [Abstract][Full Text] [Related]
11. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
[TBL] [Abstract][Full Text] [Related]
12. Eosinophilia in Hematologic Disorders.
Falchi L; Verstovsek S
Immunol Allergy Clin North Am; 2015 Aug; 35(3):439-52. PubMed ID: 26209894
[TBL] [Abstract][Full Text] [Related]
13. [Characteristics of cytogenetics and molecular biology in patients with eosinophilia].
Qu SQ; Ai XF; Li CW; Li QH; Xu ZF; Qin TJ; Zhang Y; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1216-20. PubMed ID: 23114151
[TBL] [Abstract][Full Text] [Related]
14. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.
Pardanani A; Tefferi A
Leuk Res; 2004 May; 28 Suppl 1():S47-52. PubMed ID: 15036941
[TBL] [Abstract][Full Text] [Related]
15. Myeloid neoplasms with eosinophilia.
Reiter A; Gotlib J
Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
[TBL] [Abstract][Full Text] [Related]
16. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
[TBL] [Abstract][Full Text] [Related]
17. Eosinophilic myeloid disorders.
Noel P
Semin Hematol; 2012 Apr; 49(2):120-7. PubMed ID: 22449622
[TBL] [Abstract][Full Text] [Related]
18. Eosinophilia in mast cell disease.
Kovalszki A; Weller PF
Immunol Allergy Clin North Am; 2014 May; 34(2):357-64. PubMed ID: 24745679
[TBL] [Abstract][Full Text] [Related]
19. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.
Yamada Y; Rothenberg ME; Lee AW; Akei HS; Brandt EB; Williams DA; Cancelas JA
Blood; 2006 May; 107(10):4071-9. PubMed ID: 16418325
[TBL] [Abstract][Full Text] [Related]
20. [New insights into hypereosinophilic syndromes].
Bletry O; Kahn JE; Ackermann F; Charles P; Legrand F
Bull Acad Natl Med; 2010 Mar; 194(3):547-59; discussion 559-60. PubMed ID: 21171248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
